BioSpace News Archive

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2023 financial results on Tuesday, October 31, 2023, after market close.

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2023 after market close on Monday, November 6, 2023.

Advanced Bifurcation Systems Inc. (ABS), a pioneer in comprehensive solutions for bifurcation lesions in coronary angioplasty, today announced that it has received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its novel coronary artery bifurcation stenting technology.

Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives, announced it has named Wade Rakes its Chief Growth Officer.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023.

Tevogen Bio Inc. announced the appointment of Mittul Mehta as Chief Information Officer and Head of Tevogen.ai, the newly launched initiative focused on harnessing the potential of artificial intelligence for the enhancement of drug discovery, development, manufacturing, distribution, and patient access.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an update regarding its Investigational New Drug (IND) application.

Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced the signing of a license agreement with Janssen Sciences Ireland UC (Janssen), a Johnson & Johnson (J&J) Company.

Cyclo Therapeutics, Inc. today announced that it had entered into a securities purchase agreement with certain accredited investors (the “Investors”) to raise $2,359,584 in a private offering (the “Offering”).